A Boswood, J Häggström, S G Gordon, G Wess, R L Stepien, M A Oyama, B W Keene, J Bonagura, K A MacDonald, M Patteson, S Smith, P R Fox, K Sanderson, R Woolley, V Szatmári, P Menaut, W M Church, M L O'Sullivan, J-P Jaudon, J-G Kresken, J Rush, K A Barrett, S L Rosenthal, A B Saunders, I Ljungvall, M Deinert, E Bomassi, A H Estrada, M J Fernandez Del Palacio, N S Moise, J A Abbott, Y Fujii, A Spier, M W Luethy, R A Santilli, M Uechi, A Tidholm, P Watson
BACKGROUND: Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. HYPOTHESIS/OBJECTIVES: Administration of pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not receiving other cardiovascular medications, will delay the onset of signs of CHF, cardiac-related death, or euthanasia...
November 2016: Journal of Veterinary Internal Medicine